Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Patent: 6,406,715

« Back to Dashboard

Patent 6,406,715 protects ADVICOR, NIASPAN, NIASPAN TITRATION STARTER PACK, and SIMCOR, and is included in three NDAs. There have been zero Paragraph IV challenges on Simcor and

Summary for Patent: 6,406,715

Title: Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles
Abstract:Intermediate release nicotinic acid formulations having unique urinary metabolite profiles, which are suitable for oral administration once-a-day as a single dose during a 24 hour period for treating hyperlipidemia without causing drug-induced hepatotoxicity or drug-induced elevations in uric acid or glucose or both to levels that require the therapy to be discontinued, are disclosed.
Inventor(s): Cefali; Eugenio A. (Lauderhill, FL)
Assignee: Kos Pharmaceuticals, Inc. (Miami, FL)
Application Number:08/962,423
Patent Claim Types:
see list of patent claims
Use; Formulation; Compound; Dosage form;
Patent PDF download available with subscription

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Abbvie
ADVICOR
lovastatin; niacin
TABLET, EXTENDED RELEASE;ORAL021249Dec 17, 2001RXYes6,406,715<disabled>YINTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS,SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING
Abbvie
ADVICOR
lovastatin; niacin
TABLET, EXTENDED RELEASE;ORAL021249Apr 27, 2006RXYes6,406,715<disabled>Y
Abbvie
NIASPAN
niacin
TABLET, EXTENDED RELEASE;ORAL020381Jul 28, 1997RXYes6,406,715<disabled>YINTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS,SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING
Abbvie
NIASPAN
niacin
TABLET, EXTENDED RELEASE;ORAL020381Jul 28, 1997DISCNNo6,406,715<disabled>INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS,SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING
Abbvie
NIASPAN
niacin
TABLET, EXTENDED RELEASE;ORAL020381Jul 28, 1997RXNo6,406,715<disabled>YINTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS,SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 6,406,715

Country Document Number Publication Date
World Intellectual Property Organization (WIPO)9839001Sep 11, 1998
World Intellectual Property Organization (WIPO)9839002Sep 11, 1998
United States of America5449991Sep 12, 1995
United States of America6080428Jun 27, 2000
United States of America6129930Oct 10, 2000
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc